Cancer Genetics Inc Receives Second Patent for Genomic Cervical Cancer Test; Strengthens Position of FHACT®

By Italia on November 11 2014
  • Company receives second patent (US Patent No. 8,883,414) for FHACT®
  • FHACT® has potential to improve cervical cancer detection for up to 2 million women in the US each year.

RUTHERFORD, N.J., November 11, 2014 — Cancer Genetics Inc, an emerging leader in DNA-based cancer diagnostics, announced today that it has received a second US patent covering its proprietary FISH-based HPV-Associated Cancer Test (FHACT®) for cervical cancer detection in patients.

FHACT® is designed to assess change across four biomarkers indicating HPV-associated pre-cancers and cancers. Critically, FHACT® can help prevent unnecessary colposcopies and cervical biopsies, reducing costs and complications associated with these invasive procedures.

“We are pleased to have received a second patent covering our proprietary FHACT® test. Having two patents for FHACT® further strengthens our position in this important and underserved category, and highlights the test’s unique ability to revolutionize cervical cancer detection,” said Panna Sharma, CEO of Cancer Genetics Inc.

On October 21, the United States Patent and Trademark Office (USPTO) granted CGI a product design patent for the test’s unique 4-probe combination. The additional patent granted today, November 11, covers the test’s use on clinical patient samples, including cervical tissue specimen, remnant Pap-smear fluid, or liquid based cytology. The company believes that receiving patent protection for both the FHACT® test design and for its clinical application on patient samples underscores the novelty of the test, and sets a new standard in the field of cervical cancer diagnostics.

FHACT was recently reviewed in Informa Healthcare’s Expert Reviews by Dr. Jane Houldsworth.  The review can be found in volume 14, number 8 of Expert Reviews, and is accessible online at

To learn more about FHACT®, please visit

About Cancer Genetics, Inc.

Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State.

We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended June 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.


Investor Relations
Andrew McDonald Ph.D.
Life Science Advisors LLC

Media Relations
Paul Kuntz
RedChip Companies, Inc.
800-733-2447, ext. 105

Source: Cancer Genetics, Inc.